Navigation Links
Onset Dermatologics Launches HylatopicPlus-Aurstat™ Kit
Date:2/22/2011

CUMBERLAND, R.I., Feb. 22, 2011 /PRNewswire/ -- Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of the HylatopicPlus-Aurstat™ Kit.  The kit provides two products within one package: HylatopicPlus™ Emollient Foam indicated to manage and relieve burning, itching and pain that can accompany skin dermatoses such as atopic dermatitis (eczema) and Aurstat™ Skin & Wound HydroGel, which is used to relieve skin irritation, minor abrasions and lacerations — and also can be used on intact skin.  

"We believe that the newly launched HylatopicPlus-Aurstat™ Kit provides physicians and patients greater convenience when skin barrier dysfunction and S. aureus colonization are present in the same patient," said Doug Abel, General Manager of Onset Dermatologics.  "The kit provides two therapies in one prescription for a single co-pay, which may improve patient adherence to physician instructions and thus, result in improved clinical outcomes."

HylatopicPlus™ Emollient Foam is formulated to rapidly hydrate the stratum corneum (the top layer of the epidermis) and provide a semi-permeable barrier that protects against irritants and excessive water loss through the skin. HylatopicPlus™ incorporates hyaluronic acid to deliver a blend of physiologic lipids, including ceramide, to restore healthy barrier function. HylatopicPlus™ has been clinically proven to improve the symptoms of atopic dermatitis.

Aurstat™ HydroGel is intended for over-the-counter use on minor skin abrasions and lacerations — and for use on intact skin. Aurstat™ contains a unique shelf-stable formulation of hypochlorous acid in hydrogel form. In a laboratory setting, Aurstat™ killed 99.99% of Staphylococcus aureus (S. aureus) within 30 seconds post-application.   Aurstat™ HydroGel is non-irritating and can be safely used around the eyes, nose and mouth.

The HylatopicPlus-Aurstat™ Kit is now available in the U.S. by prescription only.

Important Safety Information for HylatopicPlus™ Emollient Foam

HylatopicPlus™ is contraindicated in persons with a known hypersensitivity to any of the components of the formulation. If clinical signs of infection are present, appropriate treatment should be initiated; use of HylatopicPlus™ Emollient Foam may be continued

during the anti-infective therapy.

About Onset Dermatologics

Onset Dermatologics (www.onsetdermatologics.com) is dedicated to providing new, optimized, innovative, practical and cost-effective pharmaceutical products to the healthcare market in an effort to improve the quality of life for patients. The company markets 11 products based on its proprietary Delevo® foam technology platform that is designed to deliver enhanced penetration of proven active ingredients while improving patient compliance.

About PreCision Dermatology, Inc.

Headquartered in Cumberland RI, PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology will expand quickly through acquisitions, in-licensing, co-marketing opportunities as well as internally generated therapies.  


'/>"/>
SOURCE Onset Dermatologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Treatment for Prescription Drug Addiction and Painkiller Abuse has Risen Sharply Since Onset of Financial Crisis, Reflecting Uncertainty About Economy
2. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
3. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
4. Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa®
5. Depression and Cognitive Disorders: at the Onset of Alzheimers Disease
6. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. FDA Approves New Treatment for Late-Onset Pompe Disease
10. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
11. New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):